October 15, 2012
By Jim Moore
Potential passengers grounded by motion sickness may soon have a more effective medication to treat that queasy feeling. NASA has adapted a tried-and-true cure for delivery via nasal spray, a method that brings more rapid relief.
The space agency announced Oct. 12 a deal with Epiomed Therapeutics Inc., a California firm that aims to bring intranasal scopolamine (INSCOP, as NASA calls it) to the wider world.
"NASA and Epiomed will work closely together on further development of INSCOP to optimize therapeutic efficiency for both acute and chronic treatment of motion sickness which can be used by NASA, the Department of Defense and world travelers on land, in the air and on the seas," said Lakshmi Putcha, developer of the innovative treatment strategy at Johnson Space Center.
A nasal delivery produced promising results during tests at the Naval Aerospace Medical Research Laboratory in Pensacola, Fla., and the U.S. Navy is also working on an agreement to collaborate with Epiomed.
Clinical trials must still be conducted to secure approval from the Food and Drug Administration.
AOPA Online Associate Editor Jim Moore joined AOPA in 2011 and is an instrument-rated private pilot who enjoys competition aerobatics.
The widespread presence of angle-of-attack indicators in general aviation aircraft could reduce fatal loss-of-control accidents caused by inadvertent stalls, said the FAA.
Flight Design says production and testing of its four-seat C4 is on target despite the ongoing conflict in Ukraine.
Hartzell Engine Technologies LLC announced July 29 that it finalized an agreement to buy the assets of Granbury, Texas-based Plane-Power LTD.
VOLUNTEER AT AN AOPA FLY-IN NEAR YOU!
SHARE YOUR PASSION. VOLUNTEER AT AN AOPA FLY-IN. CLICK TO LEARN MORE >>>
VOLUNTEER LOCALLY AT AOPA FLY-IN! CLICK TO LEARN MORE >>>
BE A PART OF THE FLY-IN VOLUNTEER CREW! CLICK TO LEARN MORE >>>